Table 2.
Patient clinicopathological features
| Age, years | 41.63 ± 8.55 |
| 40 (18 to 67) | |
| Disease course, months | 7.71 ± 5.02 |
| 7 (1 to 26) | |
| Sex | |
| Male | 286 (59.46) |
| Female | 195 (40.54) |
| Preoperative steroids | |
| No | 160 (33.26) |
| Yes | 321 (66.74) |
| MGFA class | |
| I | 4 (0.83) |
| IIA | 108 (22.45) |
| IIB | 134 (27.86) |
| IIIA | 115 (23.91) |
| IIIB | 101 (21.00) |
| IVA + IVB + V | 19 (3.95) |
| Surgical approach | |
| Sternotomy | 437 (90.85) |
| VATS | 44 (9.15) |
| Postoperative myasthenic crisis | |
| No | 441 (91.68) |
| Yes | 40 (8.32) |
| Masaoka-Koga stage | |
| I | 429 (89.19) |
| IIa | 21 (4.37) |
| IIb | 25 (5.20) |
| IIIa | 6 (1.25) |
| WHO pathologic type | |
| A | 14 (2.91) |
| AB | 56 (11.64) |
| B1 | 148 (30.77) |
| B2 | 173 (35.97) |
| B3 | 90 (18.71) |
| Tumor size | |
| ≤ 5 cm | 419 (87.11) |
| > 5 cm | 62 (12.89) |
| Complete resection | |
| No | 16 (3.33) |
| Yes | 465 (96.67) |
Age and disease course presented as mean ± standard deviation and median (range); other data presented as count (percentage)
MGFA, Myasthenia Gravis Foundation of America; VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization